{"id":"https://genegraph.clinicalgenome.org/r/5764b2cb-6f85-4b47-b2fc-4bc174afc044v1.1","type":"EvidenceStrengthAssertion","dc:description":"The ANTXR2 gene is located on chromosome 4q21.21 and encodes a 55 kDa type I transmembrane protein. ANTXR2 was first reported in relation to autosomal recessive hyaline fibromatosis syndrome in 2003 (Hanks et al., PMID: 14508707; Dowling et al., PMID: 12973667). Hyaline fibromatosis syndrome (HFS) is characterized by accumulation of amorphous, unidentified hyaline material in the skin and other organs. Clinical features of HFS include progressive contractures, hyperpigmented skin over bony prominences, subcutaneous nodules, gingival thickening, and failure to thrive secondary to protein-losing enteropathy. HFS is a progressive disease and its manifestations tend to be additive over time. At least 50 variants (including missense, nonsense, frameshift, deletions, and splice variants) have been reported in the literature. Nine variants, including 5 missense variants and 4 frameshift variants that have been reported in 7 probands in four publications are included in this curation (PMID: 12973667; Deuquet et al., 2011, PMID: 21328543; Denadai et al., 2012, PMID: 22383261; Mohamed et al., 2017, PMID: 25458638). The gene-disease relationship is supported by markedly reduced protein expression in patient cells (Burgi et al., 2017, PMID: 28604699), homozygous knockout mice (PMID: 28604699), and rescue of protein expression in patient cells (PMID: 21328543; Burgi et al., 2020, PMID: 32428455). In summary, there is definitive evidence to support the relationship between ANTXR2 and autosomal recessive hyaline fibromatosis syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Syndromic Disorders GCEP on the meeting date 11.22.2022 (SOP Version 9.0).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/5764b2cb-6f85-4b47-b2fc-4bc174afc044","GCISnapshot":"https://genegraph.clinicalgenome.org/r/0368b332-6765-451e-867b-71dd93e05ae4","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/0368b332-6765-451e-867b-71dd93e05ae4_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10060","date":"2022-11-22T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/0368b332-6765-451e-867b-71dd93e05ae4_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10060","date":"2024-01-22T19:54:10.339Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0368b332-6765-451e-867b-71dd93e05ae4_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4709af9-6e08-416b-8704-0d9c49a6d9a7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4709af9-6e08-416b-8704-0d9c49a6d9a7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21328543","rdfs:label":"Deuquet_Family 3 proband","ageType":"AgeAtDiagnosis","ageUnit":"Weeks","ageValue":6,"allele":{"id":"https://genegraph.clinicalgenome.org/r/6dae80cc-2f22-4912-b633-4f54282ab351","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_058172.6(ANTXR2):c.945T>G (p.Cys315Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357473354"}},"firstTestingMethod":"PCR","phenotypeFreeText":"Failure to thrive\n","phenotypes":["obo:HP_0005876","obo:HP_0000212","obo:HP_0002014","obo:HP_0001482"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/bd63029d-2103-4445-a35a-e3de6f8b2359_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21328543","allele":{"id":"https://genegraph.clinicalgenome.org/r/6dae80cc-2f22-4912-b633-4f54282ab351"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/bd63029d-2103-4445-a35a-e3de6f8b2359","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd63029d-2103-4445-a35a-e3de6f8b2359_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/bd63029d-2103-4445-a35a-e3de6f8b2359_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reduced protein expression and mRNA levels observed (Fig 2A and 2B) in patient-derived fibroblast. Functional study done showed that C315W lead to aberrant disulphide bond formation and severe ER retention (Fig 7C).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/b4f0f88a-6a1e-4a26-aa35-42e61f0c7534_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4f0f88a-6a1e-4a26-aa35-42e61f0c7534","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21328543","rdfs:label":"Deuquet_Family 4 proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/20b18977-5003-419a-820e-686dfb729723","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_058172.6(ANTXR2):c.1073dup (p.Ala359CysfsTer13)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252353"}},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0001482","obo:HP_0000212","obo:HP_0005876","obo:HP_0002014"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1340ecfc-f63e-46d3-b32f-79f09cd37b1d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21328543","allele":{"id":"https://genegraph.clinicalgenome.org/r/20b18977-5003-419a-820e-686dfb729723"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/1340ecfc-f63e-46d3-b32f-79f09cd37b1d","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1340ecfc-f63e-46d3-b32f-79f09cd37b1d_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/1340ecfc-f63e-46d3-b32f-79f09cd37b1d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reduced protein expression and mRNA levels observed (Fig 2A and 2B) in patient-derived fibroblast, consistent with functional study done by Yan et al, 2013 (PMID 23554269). Decreased mRNA levels (Supp. Fig S1) observed presumably due to NMD pathway.","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/51de05c8-ee87-4b75-a642-85955925a035_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51de05c8-ee87-4b75-a642-85955925a035","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12973667","rdfs:label":"Family JHF1 - Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/215f332c-70e7-42a3-aa2a-0cbe36b96a19","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_058172.6(ANTXR2):c.314G>A (p.Gly105Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252345"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0000939","obo:HP_0000169","obo:HP_0000938","obo:HP_0005876","obo:HP_0001482"],"previousTesting":true,"previousTestingDescription":"Haplotype analysis was performed using eight fluorescently labeled microsatellite markers","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/f2fa1218-2029-44bb-860d-fef1238906d0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12973667","allele":{"id":"https://genegraph.clinicalgenome.org/r/215f332c-70e7-42a3-aa2a-0cbe36b96a19"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/f2fa1218-2029-44bb-860d-fef1238906d0","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2fa1218-2029-44bb-860d-fef1238906d0_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f2fa1218-2029-44bb-860d-fef1238906d0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional study done by Deuquet et al., 2009 (PMID 19191226). Ectodomain of p.G105D CMG2/ANTXR2 can fold properly (Fig  3A) and acquire a PA-binding competent form (Fig 5B), but folding in the cellular context occurs at a greatly reduced rate resulting in protein being targeted for degradation by ER quality control. (Fig 4A-D).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/57be19fc-251e-435c-8d17-27dacc4f0588_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57be19fc-251e-435c-8d17-27dacc4f0588","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25458638","rdfs:label":"Mohamed_Proband 1","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/bc399445-9a26-4ff8-9ab8-a79093a41436","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_058172.6(ANTXR2):c.134T>C (p.Leu45Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10602936"}},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0005876","obo:HP_0000212","obo:HP_0002719","obo:HP_0001482"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/41b0470e-682a-440c-b781-bcb097b8133e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25458638","allele":{"id":"https://genegraph.clinicalgenome.org/r/bc399445-9a26-4ff8-9ab8-a79093a41436"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/41b0470e-682a-440c-b781-bcb097b8133e","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/41b0470e-682a-440c-b781-bcb097b8133e_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/41b0470e-682a-440c-b781-bcb097b8133e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional study done by Deuquet et al, 2009 (PMID 19191226) demonstrate that L45P leads to abnormal localization of protein in the cell and improper folding of the von Willebrand factor domain; leading to ER retention (Fig 4A) and  subsequent degradation by ER quality control (Fig 4A-D).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/4babb232-9028-41c1-8af7-9d5d02e72fbd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4babb232-9028-41c1-8af7-9d5d02e72fbd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12973667","rdfs:label":"Family ISH2 - Proband ","allele":[{"id":"https://genegraph.clinicalgenome.org/r/00f7c5e5-1da7-4c31-b4ba-30cf61cd257c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_058172.6(ANTXR2):c.566T>C (p.Ile189Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252351"}},{"id":"https://genegraph.clinicalgenome.org/r/20b18977-5003-419a-820e-686dfb729723"}],"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"Deposition of hyaline material throughout skin","phenotypes":["obo:HP_0005876","obo:HP_0000212","obo:HP_0000938","obo:HP_0000939","obo:HP_0001482"],"previousTesting":true,"previousTestingDescription":"Haplotype analysis was performed using eight fluorescently labeled microsatellite markers","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/403835a2-c9f6-4df8-ac67-fdf4f33fb54f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12973667","allele":{"id":"https://genegraph.clinicalgenome.org/r/20b18977-5003-419a-820e-686dfb729723"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/62781d90-af9e-4635-84e4-ae5d11806c91_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12973667","allele":{"id":"https://genegraph.clinicalgenome.org/r/00f7c5e5-1da7-4c31-b4ba-30cf61cd257c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/62781d90-af9e-4635-84e4-ae5d11806c91","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62781d90-af9e-4635-84e4-ae5d11806c91_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/62781d90-af9e-4635-84e4-ae5d11806c91_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional study done by Deuquet et al., 2009 (PMID 19191226). Ectodomain of p.I189T mutants can fold properly (Fig  3A) and acquire a PA-binding competent form (Fig 5B), but folding in the cellular context occurs at a greatly reduced rate resulting in protein being targeted for degradation by ER quality control. (Fig 4A-D).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/403835a2-c9f6-4df8-ac67-fdf4f33fb54f","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/403835a2-c9f6-4df8-ac67-fdf4f33fb54f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/403835a2-c9f6-4df8-ac67-fdf4f33fb54f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional study done by Yan et al, 2013 (PMID 23554269). Decreased mRNA levels (Supp. Fig S1) observed presumably due to NMD pathway.","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/0368b332-6765-451e-867b-71dd93e05ae4_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a5755964-fb57-41a3-be9f-f677d54023b3_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28103792","rdfs:label":"Haidar_Lebanese family","estimatedLodScore":1.7,"family":{"id":"https://genegraph.clinicalgenome.org/r/a5755964-fb57-41a3-be9f-f677d54023b3","type":"Family","rdfs:label":"Haidar_Lebanese family"},"meetsInclusionCriteria":true,"phenotype":[{"id":"obo:HP_0001482"},{"id":"obo:HP_0000212"}],"phenotypeNegativeAlleleNegative":4,"phenotypePositiveAllelePositive":3,"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2ebd548b-ce24-4b19-a4f4-396f612bd4e0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ebd548b-ce24-4b19-a4f4-396f612bd4e0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12973667","rdfs:label":"Family JHF2 - Proband ","allele":{"id":"https://genegraph.clinicalgenome.org/r/c03ec151-6ce1-41a4-a036-24f0c243a41d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_058172.6(ANTXR2):c.986T>G (p.Leu329Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252347"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"Deposition of hyaline material throughout skin","phenotypes":["obo:HP_0001482","obo:HP_0000212"],"previousTesting":true,"previousTestingDescription":"Haplotype analysis was performed using eight fluorescently labeled microsatellite markers","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/f384f166-10f1-4ef3-96ad-2fd9c8948e9a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12973667","allele":{"id":"https://genegraph.clinicalgenome.org/r/c03ec151-6ce1-41a4-a036-24f0c243a41d"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/f384f166-10f1-4ef3-96ad-2fd9c8948e9a","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f384f166-10f1-4ef3-96ad-2fd9c8948e9a_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f384f166-10f1-4ef3-96ad-2fd9c8948e9a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional study done by Deuquet et al., 2009 (PMID 19191226). p.L329R mutations lead to severe ER retention phenotype, even though folding is expected to be successful and leads to PA-binding competent ectodomain as p.L329R mutation is not in the CMG2 ectodomain; but mutant protein is being targeted for degradation by ER quality control. (Fig 4C).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/2a8f239e-e0cc-40be-b608-d6eb213c2484_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a8f239e-e0cc-40be-b608-d6eb213c2484","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22383261","rdfs:label":"Denadai_Family 3 proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/20b18977-5003-419a-820e-686dfb729723"},{"id":"https://genegraph.clinicalgenome.org/r/76f43ede-d6d5-45d0-809a-e1db13f2e8be","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_058172.6(ANTXR2):c.1074del (p.Ala359HisfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2981725"}}],"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Failure to thrive. Deposition of hyaline material throughout the skin.","phenotypes":["obo:HP_0002014","obo:HP_0001482","obo:HP_0005876"],"previousTesting":false,"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/410456f4-3875-43c2-87ca-7062e0b27e01_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22383261","allele":{"id":"https://genegraph.clinicalgenome.org/r/76f43ede-d6d5-45d0-809a-e1db13f2e8be"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/22a67ab3-6cd7-4dea-853b-723fea2e7708_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22383261","allele":{"id":"https://genegraph.clinicalgenome.org/r/20b18977-5003-419a-820e-686dfb729723"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/410456f4-3875-43c2-87ca-7062e0b27e01","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/410456f4-3875-43c2-87ca-7062e0b27e01_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/410456f4-3875-43c2-87ca-7062e0b27e01_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional study done by Yan et al, 2013 (PMID 23554269). Decreased mRNA levels observed (Supp. Fig S1) and ANTXR2delT resulted in different properties of cytosolic tail that are rapidly degraded by NMD pathway (Fig 2A-E)","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/22a67ab3-6cd7-4dea-853b-723fea2e7708","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22a67ab3-6cd7-4dea-853b-723fea2e7708_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/22a67ab3-6cd7-4dea-853b-723fea2e7708_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional study done by Yan et al, 2013 (PMID 23554269). Decreased mRNA levels (Supp. Fig S1) observed presumably due to NMD pathway.","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/0368b332-6765-451e-867b-71dd93e05ae4_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0368b332-6765-451e-867b-71dd93e05ae4_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/866cf609-6bc5-4186-807b-52469b474df8","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eaf1ad50-bb03-47ee-b1d4-fade434c0f65","type":"FunctionalAlteration","dc:description":"Markedly reduced CMG2 mRNA expression in patient's fibroblast (Supp Fig 6b). Patient's fibroblasts were unable to degrade collagen VI even if the complex was found associated with cells.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28604699","rdfs:label":"Collagen VI degradation inhibited in patient fibroblast"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0368b332-6765-451e-867b-71dd93e05ae4_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5a0975af-118e-438f-bc91-2110a29e15c0","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ff1c59c2-dd7e-4b71-8121-bb618557466d","type":"Finding","dc:description":"Patient cells were recomplemented with WT CMG2 using lentiviral vectors. Cells recomplemented with WT CMG2 restored the ability to degrade collagen VI.  ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32428455","rdfs:label":"Rescue of Collagen VI degradation function","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d9334d32-6d06-4590-879e-78ff736a078d","type":"EvidenceLine","dc:description":"Downgraded as it is a therapeutic approach rather than experiment using WT to rescue the phenotype","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/872c4563-edea-456e-b95a-2044ac178047","type":"Finding","dc:description":"CMG2 protein levels could be restored to approximate control levels as the protein was properly targeted to the plasma membrane and signalling competent (Fig 8A).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21328543","rdfs:label":"Rescue of CMG2/ATXR2 expression by proteasome inhibitors","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ee810562-72d3-4303-b957-f5dfd56f5047","type":"EvidenceLine","dc:description":"Not scoring -  does not fit human disease phenotype","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5fa8c3ef-fcb2-4b21-a967-97d199e96c4e","type":"Finding","dc:description":"Antxr2-/-::Col6a1-/- double knockout mice are fertile, with complete restoration of the uterine myometrial layers","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28604699","rdfs:label":"Double knockout female mice","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2130044c-60aa-489c-89f9-5e0c8df024e6","type":"EvidenceLine","dc:description":"Downgraded as it does not fit human disease phenotype","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/38499d4a-ee09-49c4-8030-90102ef672ea","type":"Finding","dc:description":"Uteri of Antxr2-/- female mice are highly enriched in collagen VI (Fig 3a). HFS patient nodules showed accumulation of collagen VI.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28604699","rdfs:label":"Antxr2 mice knockout","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3}],"evidenceStrength":"Definitive","sequence":7645,"specifiedBy":"GeneValidityCriteria10","strengthScore":15,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Z9fBQ4gU2_g","type":"GeneValidityProposition","disease":"obo:MONDO_0009229","gene":"hgnc:21732","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_0368b332-6765-451e-867b-71dd93e05ae4-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}